Lee's Pharmaceutical Holdings Limited (HKG:0950)

Market Cap	624.17M -19.7%
Revenue (ttm)	1.44B +2.6%
Net Income	91.94M -1.2%
EPS	0.16 -1.3%
Shares Out	588.84M
PE Ratio	6.79
Forward PE	n/a
Dividend	0.05 (4.25%)
Ex-Dividend Date	May 27, 2026

Volume	1,117,000
Open	1.060
Previous Close	1.060
Day's Range	1.060 - 1.170
52-Week Range	0.990 - 2.700
Beta	0.56
Analysts	n/a
Price Target	n/a
Earnings Date	Mar 30, 2026

About HKG:0950

Lee's Pharmaceutical Holdings Limited, an investment holding company, develops, manufactures, markets, and sells pharmaceutical products in the People's Republic of China, Hong Kong, and internationally. It focuses on various disease areas, such as cardiovascular, woman’s health, pediatrics, rare diseases, oncology, dermatology, and obstetrics. It operates in Proprietary and Generic Products; and Licensed-In Products segments. The Proprietary and Generic Products segment manufactures and sells Nadroparin Calcium injection and Livaracine to trea...

• Industry: Drug Manufacturers - Specialty & Generic
• Sector: Healthcare
• Founded: 1994
• Employees: 1,094
• Stock Exchange: Hong Kong Stock Exchange
• Ticker Symbol: 0950

Financial Performance

In 2025, HKG:0950's revenue was 1.44 billion, an increase of 2.57% compared to the previous year's 1.40 billion. Earnings were 91.94 million, a decrease of -1.25%.